Skip to Content

Press Releases

Press Releases

Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
Jun 09, 2022
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
Jun 09, 2022
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
Jun 08, 2022
Tiziana Life Sciences to Present at the 2022 Biotechnology Innovation Organization Annual Convention to Discuss Recent Updates to Ongoing Clinical Programs
Jun 06, 2022
Data from Secondary Progressive Multiple Sclerosis Patient Treated with Intranasal Treatment with Foralumab will be Presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2022 Annual Meeting
Jun 01, 2022
Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
May 24, 2022
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
Apr 26, 2022
FDA Grants Permission to Enroll up to 8 Additional Secondary Progressive Multiple Sclerosis (SPMS) Patients in the Expanded Access Program with Intranasal Foralumab
Apr 05, 2022
Tiziana Announces Initiation of Phase 1b Clinical Trial in Crohn’s Disease Patients to Evaluate Oral Capsules of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Mar 25, 2022
Tiziana Announces Availability of March 14 KOL Event Replay
Mar 15, 2022
Displaying 31 - 40 of 423